GC Pharma Corp., formerly Green Cross Corp., of Yongin, South Korea, plans to start enrollment in a phase II/III trial testing GC-1102 (hepabig-gene) to prevent the recurrence of hepatitis B virus infection following liver transplantation in early 2018. Read More
The Cell and Gene Therapy (CGT) Catapult, of London, announced a partnership with London-based Freeline Therapeutics Ltd., a company focused on the development of adeno-associated virus-based gene therapies, to further develop the company's manufacturing platform at the CGT Catapult's large-scale GMP manufacturing center in Stevenage, Hertfordshire, U.K. Read More
GPB Capital Holdings LLC, of New York, made a debt investment in Torrance, Calif.-based Emmaus Life Sciences Inc. consisting of a $30 million senior secured convertible note with warrants, with $20 million in proceeds delivered up front. Read More
Circle Pharma Inc., of South San Francisco, said its first collaboration with Pfizer Inc. has led to the identification of a series of bioavailable macrocyclic peptides capable of acting as potent and cell-permeable modulators of CXCR7. Read More
LONDON – Drug discovery in the U.K. needs to be radically reshaped, ditching "irrelevant" animal models in favor of more testing on human tissues and cells, according to a new report by the Medicines Discovery Catapult (MDC). Read More
SHANGHAI – Beigene Ltd. nabbed the Asia-Pacific rights to sitravatinib from Mirati Therapeutics Inc. in a $10 million cash deal, valued at $123 million when additional milestones roll in. The Beijing-based firm also just announced a $750 million public offering to support its growing immuno-oncology pipeline. Read More
With more than two decades of experience in immunology and inflammatory diseases, Anthony Coyle was hankering for the opportunity to shift the treatment paradigm from systemic immunosuppressives, which temper disease but come with long-term consequences to patients, to "a different type of approach" that would modulate the immune system. Read More
